Skip to main content

Ascendis Pharma A/S (ASND) Stock Forecast

Data as of Aug 5, 2026

Healthcare · Current price $243.46 (+0.00%)

Consensus Target
$287.50
Upside
+18.9%
Analysts
8
Rating
Buy(2.00)

Price Target Range

Low $250.00Consensus $287.50High $345.00
▲ Current $243.46

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy3
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

ASND vs Sector & Market

MetricASNDHealthcare AvgLarge Cap Avg
Analyst Rating2.002.252.42
Analyst Count8818
Target Upside+18.9%+16316.2%+17.1%
P/E Ratio-51.063.3736.31

Revenue Estimates

PeriodLowAvgHigh#
2026-09-30$337M$371M$406M4
2026-12-31$382M$421M$460M7
2027-03-31$386M$424M$464M4
2027-06-30$410M$451M$494M6
2027-09-30$444M$489M$535M4
2027-12-31$488M$536M$587M7

EPS Estimates

PeriodLowAvgHigh#
2026-09-30$1.11$1.26$1.423
2026-12-31$1.52$1.73$1.946
2027-03-31$1.38$1.56$1.753
2027-06-30$1.55$1.76$1.975
2027-09-30$1.84$2.08$2.343
2027-12-31$2.25$2.55$2.876

Frequently Asked Questions

What is the analyst consensus for ASND?

The consensus among 8 analysts covering Ascendis Pharma A/S (ASND) is Buy with an average price target of $287.50.

What is the highest price target for ASND?

The highest analyst price target for ASND is $345.00.

What is the lowest price target for ASND?

The lowest analyst price target for ASND is $250.00.

How many analysts cover ASND?

8 analysts have issued ratings for Ascendis Pharma A/S in the past 12 months.

Is ASND a buy or sell right now?

Based on 8 analyst ratings, ASND has a consensus rating of Buy (2.00/5) with a +18.9% upside to the consensus target of $287.50.

What are the earnings estimates for ASND?

Analysts estimate ASND will report EPS of $1.26 for the period ending 2026-09-30, with revenue estimated at $371M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.